EXACT THERAPEUTICS Exact Therapeutics AS to present atDNB Nordic Healthcare Conference on16th December 2021 OSLO /LONDON :13 DECEMBER, 2021 :Exact Therapeutics AS ("EXACT-Tx", or "the Company" Euronext Growth: EXTX), a clinical-stage precision health company evaluating Acoustic Cluster Therapy (ACT®) across multiple therapeutic areas, today announces that its Interim Chief Executive Officer and Chief Financial Officer,Dominic Moreland and Chief Medical Officer, DrHilary McElwaine-Johnn will present a corporate overview via live webcast at the DNB Nordic Healthcare Conference 6th at3:55pm CET . The Management Team is also available for 1:1 meetings with potential partners and investors. The presentation will be available at www.exact-tx.com. DNB isNorway's largest financial services group and one of the largest in the Nordic region in terms of market capitalisation. The Group offers a full range of financial services, including loans, savings, advisory services, insurance and pension products for retail and corporate customers. END For more information, please contact:Dominic Moreland EXACT Therapeutics Email: dominic@exact-tx.comOptimum Strategic Communications Mary Clark/Manel Mateus / Vici Rabbets Tel: +44 (0) 208 078 0457 Email: Exact@optimumcomms.com About EXACT EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®). ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement - with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases. www.exact-tx.com About ACT® oACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. oACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as blood-brain barrier penetration. oInitial focus of the Company is in oncology, however the ACT® platform has potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and product classes.
Click here for more information
© Oslo Bors ASA, source
